Cargando…

Identifying Human Specific Adverse Outcome Pathways of Per- and Polyfluoroalkyl Substances Using Liver-Chimeric Humanized Mice

BACKGROUND: Per- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants with myriad adverse effects. While perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) are the most common contaminants, levels of replacement PFAS, such as perfluoro-2-methyl-3-oxahexanoic ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Robarts, Dakota R., Paine-Cabrera, Diego, Kotulkar, Manasi, Venneman, Kaitlyn K., Gunewardena, Sumedha, Corton, J. Christopher, Lau, Christopher, Foquet, Lander, Bial, Greg, Apte, Udayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915685/
https://www.ncbi.nlm.nih.gov/pubmed/36778348
http://dx.doi.org/10.1101/2023.02.01.526711
_version_ 1784885950068817920
author Robarts, Dakota R.
Paine-Cabrera, Diego
Kotulkar, Manasi
Venneman, Kaitlyn K.
Gunewardena, Sumedha
Corton, J. Christopher
Lau, Christopher
Foquet, Lander
Bial, Greg
Apte, Udayan
author_facet Robarts, Dakota R.
Paine-Cabrera, Diego
Kotulkar, Manasi
Venneman, Kaitlyn K.
Gunewardena, Sumedha
Corton, J. Christopher
Lau, Christopher
Foquet, Lander
Bial, Greg
Apte, Udayan
author_sort Robarts, Dakota R.
collection PubMed
description BACKGROUND: Per- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants with myriad adverse effects. While perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) are the most common contaminants, levels of replacement PFAS, such as perfluoro-2-methyl-3-oxahexanoic acid (GenX), are increasing. In rodents, PFOA, PFOS, and GenX have several adverse effects on the liver, including nonalcoholic fatty liver disease. OBJECTIVE: We aimed to determine human-relevant mechanisms of PFAS induced adverse hepatic effects using FRG liver-chimeric humanized mice with livers repopulated with functional human hepatocytes. METHODS: Male humanized mice were treated with 0.067 mg/L of PFOA, 0.145 mg/L of PFOS, or 1 mg/L of GenX in drinking water for 28 days. Liver and serum were collected for pathology and clinical chemistry, respectively. RNA-sequencing coupled with pathway analysis was used to determine molecular mechanisms. RESULTS: PFOS caused a significant decrease in total serum cholesterol and LDL/VLDL, whereas GenX caused a significant elevation in LDL/VLDL with no change in total cholesterol and HDL. PFOA had no significant changes in serum LDL/VLDL and total cholesterol. All three PFAS induced significant hepatocyte proliferation. RNA-sequencing with alignment to the human genome showed a total of 240, 162, and 619 differentially expressed genes after PFOA, PFOS, and GenX exposure, respectively. Upstream regulator analysis revealed inhibition of NR1D1, a transcriptional repressor important in circadian rhythm, as the major common molecular change in all PFAS treatments. PFAS treated mice had significant nuclear localization of NR1D1. In silico modeling showed PFOA, PFOS, and GenX potentially interact with the DNA-binding domain of NR1D1. DISCUSSION: These data implicate PFAS in circadian rhythm disruption via inhibition of NR1D1. These studies show that FRG humanized mice are a useful tool for studying the adverse outcome pathways of environmental pollutants on human hepatocytes in situ.
format Online
Article
Text
id pubmed-9915685
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-99156852023-02-11 Identifying Human Specific Adverse Outcome Pathways of Per- and Polyfluoroalkyl Substances Using Liver-Chimeric Humanized Mice Robarts, Dakota R. Paine-Cabrera, Diego Kotulkar, Manasi Venneman, Kaitlyn K. Gunewardena, Sumedha Corton, J. Christopher Lau, Christopher Foquet, Lander Bial, Greg Apte, Udayan bioRxiv Article BACKGROUND: Per- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants with myriad adverse effects. While perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS) are the most common contaminants, levels of replacement PFAS, such as perfluoro-2-methyl-3-oxahexanoic acid (GenX), are increasing. In rodents, PFOA, PFOS, and GenX have several adverse effects on the liver, including nonalcoholic fatty liver disease. OBJECTIVE: We aimed to determine human-relevant mechanisms of PFAS induced adverse hepatic effects using FRG liver-chimeric humanized mice with livers repopulated with functional human hepatocytes. METHODS: Male humanized mice were treated with 0.067 mg/L of PFOA, 0.145 mg/L of PFOS, or 1 mg/L of GenX in drinking water for 28 days. Liver and serum were collected for pathology and clinical chemistry, respectively. RNA-sequencing coupled with pathway analysis was used to determine molecular mechanisms. RESULTS: PFOS caused a significant decrease in total serum cholesterol and LDL/VLDL, whereas GenX caused a significant elevation in LDL/VLDL with no change in total cholesterol and HDL. PFOA had no significant changes in serum LDL/VLDL and total cholesterol. All three PFAS induced significant hepatocyte proliferation. RNA-sequencing with alignment to the human genome showed a total of 240, 162, and 619 differentially expressed genes after PFOA, PFOS, and GenX exposure, respectively. Upstream regulator analysis revealed inhibition of NR1D1, a transcriptional repressor important in circadian rhythm, as the major common molecular change in all PFAS treatments. PFAS treated mice had significant nuclear localization of NR1D1. In silico modeling showed PFOA, PFOS, and GenX potentially interact with the DNA-binding domain of NR1D1. DISCUSSION: These data implicate PFAS in circadian rhythm disruption via inhibition of NR1D1. These studies show that FRG humanized mice are a useful tool for studying the adverse outcome pathways of environmental pollutants on human hepatocytes in situ. Cold Spring Harbor Laboratory 2023-02-03 /pmc/articles/PMC9915685/ /pubmed/36778348 http://dx.doi.org/10.1101/2023.02.01.526711 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Robarts, Dakota R.
Paine-Cabrera, Diego
Kotulkar, Manasi
Venneman, Kaitlyn K.
Gunewardena, Sumedha
Corton, J. Christopher
Lau, Christopher
Foquet, Lander
Bial, Greg
Apte, Udayan
Identifying Human Specific Adverse Outcome Pathways of Per- and Polyfluoroalkyl Substances Using Liver-Chimeric Humanized Mice
title Identifying Human Specific Adverse Outcome Pathways of Per- and Polyfluoroalkyl Substances Using Liver-Chimeric Humanized Mice
title_full Identifying Human Specific Adverse Outcome Pathways of Per- and Polyfluoroalkyl Substances Using Liver-Chimeric Humanized Mice
title_fullStr Identifying Human Specific Adverse Outcome Pathways of Per- and Polyfluoroalkyl Substances Using Liver-Chimeric Humanized Mice
title_full_unstemmed Identifying Human Specific Adverse Outcome Pathways of Per- and Polyfluoroalkyl Substances Using Liver-Chimeric Humanized Mice
title_short Identifying Human Specific Adverse Outcome Pathways of Per- and Polyfluoroalkyl Substances Using Liver-Chimeric Humanized Mice
title_sort identifying human specific adverse outcome pathways of per- and polyfluoroalkyl substances using liver-chimeric humanized mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915685/
https://www.ncbi.nlm.nih.gov/pubmed/36778348
http://dx.doi.org/10.1101/2023.02.01.526711
work_keys_str_mv AT robartsdakotar identifyinghumanspecificadverseoutcomepathwaysofperandpolyfluoroalkylsubstancesusingliverchimerichumanizedmice
AT painecabreradiego identifyinghumanspecificadverseoutcomepathwaysofperandpolyfluoroalkylsubstancesusingliverchimerichumanizedmice
AT kotulkarmanasi identifyinghumanspecificadverseoutcomepathwaysofperandpolyfluoroalkylsubstancesusingliverchimerichumanizedmice
AT vennemankaitlynk identifyinghumanspecificadverseoutcomepathwaysofperandpolyfluoroalkylsubstancesusingliverchimerichumanizedmice
AT gunewardenasumedha identifyinghumanspecificadverseoutcomepathwaysofperandpolyfluoroalkylsubstancesusingliverchimerichumanizedmice
AT cortonjchristopher identifyinghumanspecificadverseoutcomepathwaysofperandpolyfluoroalkylsubstancesusingliverchimerichumanizedmice
AT lauchristopher identifyinghumanspecificadverseoutcomepathwaysofperandpolyfluoroalkylsubstancesusingliverchimerichumanizedmice
AT foquetlander identifyinghumanspecificadverseoutcomepathwaysofperandpolyfluoroalkylsubstancesusingliverchimerichumanizedmice
AT bialgreg identifyinghumanspecificadverseoutcomepathwaysofperandpolyfluoroalkylsubstancesusingliverchimerichumanizedmice
AT apteudayan identifyinghumanspecificadverseoutcomepathwaysofperandpolyfluoroalkylsubstancesusingliverchimerichumanizedmice